Abstract: Transcorneal and fiberoptic laser delivery systems and methods for the treatment of eye diseases wherein energy is delivered by wavelengths transparent to the cornea to effect target tissues in the eye for the control of intraocular pressure in diseases such as glaucoma by delivery systems both external to and within ocular tissues. External delivery may be affected under gonioscopic control. Internal delivery may be controlled endoscopically or fiberoptically, both systems utilizing femtosecond laser energy to excise ocular tissue. The femtosecond light energy is delivered to the target tissues to be treated to effect precisely controlled photodisruption to enable portals for the outflow of aqueous fluid in the case of glaucoma in a manner which minimizes target tissue healing responses, inflammation and scarring.

Abstract: An ocular implant delivery system is provided with a number of features. In some embodiments, the delivery system comprises a rotation mechanism configured to rotate and orient a cannula of the system, and an advancement mechanism configured to advance and retract an ocular implant through the delivery system and into an eye of a patient. In some embodiments, the cannula is sized and configured to be inserted into Schlemm's canal of the eye. The ocular implant is configured to maintain its orientation within the delivery system as the cannula is rotated. In some embodiments, the ocular implant automatically disengages the delivery system when it is advanced beyond a distal tip of the delivery system. Methods of implanting an ocular implant are also provided.

Abstract: Devices, systems and methods for applying a bioadhesive substance to an internal surface of the eye, such as the retina, can include an outer sleeve having a proximal end, a distal end, a passageway extending along a length of the elongate body and an opening at the distal end of the elongate body, an applicator tip including an elongate body having a proximal end and a distal end, an applicator portion coupled with the distal end of the elongate body, and a substance supply lumen extending along a length of the device through which a bioadhesive substance can pass so that the bioadhesive substance can be applied to at least the applicator portion of the applicator tip. Some embodiments of the device can also have a source of the bioadhesive substance in fluid communication with at least the substance supply lumen.

Abstract: An ophthalmic device includes a housing configured to hold an injectant chamber configured to store an injectant, a plunger disposed within the injectant chamber, and a stopper coupled to a distal portion of the plunger. The device also includes a hypodermic needle disposed at a distal end of the housing, and a sample chamber located within the housing adjacent to the distal end. The housing, hypodermic needle, and sample chamber are arranged such that when the stopper is moved to a first depth within the housing, the sample chamber is configured to receive material via the hypodermic needle. The housing, hypodermic needle, and sample chamber are also arranged such that when the stopper is moved to a second depth within the housing exceeding the first depth, the injectant chamber is configured to dispense the injectant through the hypodermic needle.

Abstract: A pneumatic cross-connect proportional valve provides the capability to calibrate pressure and vacuum sensors in a surgical cassette associated with a surgical console. Calibration of non-invasive pressure and vacuum sensors in a cassette by utilizing a proportional cross-connect to pressurize the lines with set pressure or vacuum the lines with set vacuum and measure the response of respective sensors in the cassette. The use of proportional pressure may be used along with other clearing methods to clear material clogging the aspiration channel pathways and tubing of the surgical system. Utilize the cross-connect functionality to more rapidly pressurize the aspiration line upon detection or prediction of a post occlusion surge, thereby reducing the pressure difference between the surgical field, the eye chamber, and aspiration line which may prevent, for example, a surge of fluid out of the anterior chamber of the eye.

Abstract: The present disclosure relates to the discovery that certain diseases of the eye that profoundly affect the human visual system and, as a result, quality of life, may be treated using Edonentan or A-182086. Edonentan or A-182086 can be used alone or in combination with an intra-ocular pressure (IOP) reducing agent, a neuroprotective agent, an anti-VEGF agent, or all, for example. Using Edonentan or A-182086, alone or in combination with an additional agent, provides increased perfusion to the retina in certain diseases and reduces damage to retinal cells.

Abstract: Disclosed herein are implementations of a particles-transferring system, particle transferring unit, and method of transferring particles in a pattern. In one implementation, a particles-transferring system includes a first substrate including a first surface to support particles in a pattern, particle transferring unit including an outer surface to be offset from the first surface by a first gap, and second substrate including a second surface to be offset from the outer surface by a second gap. The particle transferring unit removes the particles from the first surface in response to the particles being within the first gap, secures the particles in the pattern to the outer surface, and transports the particles in the pattern. The second substrate removes the particles in the pattern from the particle transferring unit in response to the particles being within the second gap. The particles are to be secured in the pattern to the second surface.

Abstract: An apparatus includes a body, a needle, a catheter, and an actuator assembly. The needle extends distally from the body. The needle has an inner wall defining a needle lumen. The needle lumen is in fluid communication with a fluid port of the body. The catheter is slidably disposed in the needle lumen. The catheter has a catheter lumen. The first actuator assembly is configured to translate the catheter within and relative to the needle. The apparatus may also include an actuator assembly that is configured to rotate the needle relative to the body. The apparatus may be used to first deliver a leading bleb of fluid to the subretinal space in a patient's eye via the needle. The apparatus may then be used to deliver a therapeutic agent to the subretinal space in the patient's eye via the catheter.

Abstract: A hand-held or wearable device for cooling tissue of an eye of a patient is disclosed. In one aspect, the device includes a reservoir having fluid therein and a support connected to the reservoir and configured to be positioned on a face of the patient. The device also includes a nozzle positioned proximate to the support and fluidically connected to the reservoir, the nozzle configured to pass the fluid from the reservoir onto a surface of the eye. The device further includes a cooling element configured to cool the fluid from the reservoir such that it exits the nozzle at a temperature of between ?100° C. and 15° C. The device further includes an ultrasonic vibrator positioned near the nozzle and configured to generate mist from at least part of the fluid.

Abstract: Methods, systems, and compositions for maintaining functioning drainage blebs to reduce intraocular pressure (IOP) of an eye being treated for glaucoma. The methods, systems, and compositions feature the combination of a minimally invasive glaucoma surgery (MIGS) implant or procedure and the application of beta radiation to the bleb. The beta radiation can function to inhibit or reduce the inflammation and/or fibrogenesis that typically occurs after insertion of a MIGS implant and leads to bleb failure. By reducing inflammation and/or fibrogenesis, the MIGS implant and the blebs can remain functioning appropriately.

Abstract: Described here are systems and methods for accessing Schlemm's canal and for delivering an ocular device or fluid composition therein. The ocular devices may maintain the patency of Schlemm's canal without substantially interfering with transmural fluid flow across the canal. The fluid composition may be a viscoelastic fluid that is delivered into the canal to facilitate drainage of aqueous humor by disrupting the canal and surrounding trabeculocanalicular tissues. Tools for disrupting these tissues and minimally invasive methods for treating medical conditions associated with elevated intraocular pressure, including glaucoma, are also described.

Abstract: An ocular implant is provided. In some embodiments, the ocular implant includes a body that is curved about a longitudinal central axis and a distal body portion that defines a longitudinal channel including a channel opening. The implant is sized and configured such that the ocular implant assumes an orientation in which the channel opening is adjacent a major side of Schlemm's canal when the ocular implant is disposed in Schlemm's canal. Methods for delivering ocular implants into Schlemm's canal are also provided. Some methods include covering openings in the ocular implant, advancing the implant into Schlemm's canal while at least some of the openings are covered, and uncovering the openings while the distal portion of the implant is disposed in Schlemm's canal.

Abstract: An apparatus includes a housing coupled to a medicament container, which is coupled to a needle. An injection assembly is disposed within the housing and includes an energy storage member and an actuation rod. A distal end portion of the actuation rod is disposed within the medicament container. The energy storage member can produce a force on a proximal end portion of the actuation rod sufficient to move the distal end portion of the actuation rod within the medicament container. This can convey at least a portion of a substance from the medicament container via the needle when a distal tip of the needle is disposed within a first region of a target location. The force is insufficient to move the distal end portion of the actuation rod within the medicament container when the distal tip of the needle is disposed within a second region of the target location.

Abstract: Pharmaceutical compositions, methods for treating various issues of the eyes, and methods of preparing such compositions are described. These pharmaceutical compositions may be for treating glaucoma, in preparation of eye surgery, during eye surgery, various post-op care (e.g., after cataract surgery, laser eye surgery, and the like), for treating dry eyes, and/or for promoting eyelash growth. These pharmaceutical compositions may comprise such active ingredients (APIs) as: timolol, latanoprost, brimonidine tartrate, dorzolamide, moxifloxacin HCl, dexamethasone PO4, phenylephrine HCl, lidocaine HCl, ketorolac tromethamine, bromfenac, prednisolone PO4, gatifloxacin, amniotic cytokine extract (ACE), prostaglandin E2 (PGE2), and combinations thereof.

Abstract: Methods and apparatuses for automatically switching different aspiration levels to an ocular probe are disclosed herein. The probe may be a phacoemulsification probe. A first aspiration level, supplied by a first pump, may be applied to the probe simultaneously with ultrasonic energy. A second aspiration level, supplied by a second pump, may be automatically switched from the first aspiration level. Control feed back of the pumps may be varied according to set thresholds.

Abstract: The present invention relates to a device for fracturing and removing ocular lenses. The device mainly comprises a rotational screw drill, a sleeve and a hydraulic suction system. The rotational screw drill has reversed conical propellers which help to grind the particles. The rotational screw drill is housed in a sleeve, which comprises a rigid cylinder and a suction cup. The suction cup has a bell or funnel shape with an elliptical cross-section. Finally, the hydraulic suction system is key for the present invention performance. Also, the invention relates to a method comprising the steps of breaking, splitting the cataract or lens tissue and simultaneously or subsequently grinding the particles inside the sleeve by means of the rotational screw drill and the sleeve, and finally removing them from the medium via the sleeve by means of a hydraulic suction system.

Abstract: A system for storing and delivering a predetermined amount of fluid includes a syringe including a barrel, a flange disposed at the proximal end of the barrel, and a plunger assembly configured to be received in the lumen of the barrel. The plunger assembly includes a piston and a plunger rod. The plunger rod is removably couplable to the piston at the distal end of the plunger rod and includes a thumb press flange at the proximal end of the plunger rod. The system further includes a stop feature that is removably couplable to the syringe or the plunger assembly. The stop feature is configured to arrest distal advancement of the plunger assembly relative to the syringe when the plunger assembly reaches a predetermined position relative to the syringe. The stop thus ensures that a predetermined amount of fluid remains in the barrel.

Abstract: Methods and systems for automatically pulsing different aspiration levels to an ocular probe are disclosed. The probe may be a phacoemulsification probe. A first aspiration level, supplied by a first pump, may be applied to the probe simultaneously with ultrasonic energy. A second aspiration level, supplied by a second pump, may be automatically switched from the first aspiration level, and applied to the probe in a pulsed manner.

Abstract: Multilayer thin film devices that include a bioactive agent for elution to the surrounding tissue upon administration to a subject are provided. The multilayer thin film devices are useful as medical devices, such as ocular devices. Also provided are methods and kits for localized delivery of a bioactive agent to a tissue of a subject, and methods of preparing the subject devices. The multilayer thin film medical device includes a first layer, a bioactive agent and a second layer. The first and the second layers may be porous or non-porous. The devices have a furled structure, suitable for administration to a subject.

Abstract: Glaucoma patients suffer from increased intraocular pressure due to blocked fluid flow from the anterior chamber of the eye. Methods of the invention include inserting a probe into an eye of a subject having glaucoma, adjusting placement of the probe to a position transverse to Schlemm's canal in the eye, and applying a plurality of shots from an excimer laser source while the probe is in the transverse position, thereby treating glaucoma by creating a plurality of perforations in Schlemm's canal and/or the trabecular meshwork. By providing a laser probe at a position transverse to Schlemm's canal, energy from the laser is delivered to a greater amount of surface area than if the laser was arranged in a parallel or perpendicular position to Schlemm's canal, resulting in optimal formation of perforations. The perforations allow for drainage of fluid and increased outflow of aqueous humor in the eye.

Abstract: Transcorneal and fiberoptic laser delivery systems and methods for the treatment of eye diseases wherein energy is delivered by wavelengths transparent to the cornea to effect target tissues in the eye for the control of intraocular pressure in diseases such as glaucoma by delivery systems both external to and within ocular tissues. External delivery may be affected under gonioscopic control. Internal delivery may be controlled endoscopically or fiberoptically, both systems utilizing femtosecond laser energy to excise ocular tissue. The femtosecond light energy is delivered to the target tissues to be treated to effect precisely controlled photodisruption to enable portals for the outflow of aqueous fluid in the case of glaucoma in a manner which minimizes target tissue healing responses, inflammation and scarring.

Abstract: A comfortable insert comprises a retention structure sized for placement under the eyelids and along at least a portion of conjunctival sac of the upper and lower lids of the eye. The retention structure resists deflection when placed in the conjunctival sac of the eye and to guide the insert along the sac when the eye moves. The retention structure can be configured in many ways to provide the resistance to deflection and may comprise a hoop strength so as to urge the retention structure outward and inhibit movement of the retention structure toward the cornea. The insert may move rotationally with deflection along the conjunctival sac, and may comprise a retention structure having a cross sectional dimension sized to fit within folds of the conjunctiva. The insert may comprise a release mechanism and therapeutic agent to release therapeutic amounts of the therapeutic agent for an extended time.

Abstract: A biodegradable therapeutic carrier and implant comprises a layer of biodegradable electrospun material and floored wells formed by the layer to contain therapeutic.

Abstract: An improved formulation of an ophthalmic composition contains riboflavin, as cross-linking agent of corneal collagen, administered by corneal iontophoresis, able to guarantee an increased capacity of permeation of riboflavin of the corneal stroma and therefore greater therapeutic efficacy in the treatment of keratoconus.

Abstract: The present invention provides a formulation comprising a corticosteroid and an insulin analog or pharmaceutical compositions thereof. Also provided is a formulation comprising a corticosteroid, insulin lispro and at least one organic acid or pharmaceutical compositions thereof. The present invention provides methods for stimulating bone and/or cartilage growth, for treating tendon and/or ligament damage, for stimulating hair growth and/or reducing hair loss, for stimulating growth of a tooth and/or periodontium and for treating tumors and cysts of the jaw by administering the formulations described herein.

Abstract: A method of treating glaucoma or other eye disease in a patient is provided. The method includes injecting an eye of the patient with a cohesive monophasic gel containing cross-linked hyaluronic acid or its salt. The injection can be under the scleral flap and/or conjunctiva of the eye, thereby creating and maintaining a conjunctival bleb, and/or the injection can be in the supra-scleral and/or supra-choroidal (sub-scleral) space of the eye thereby reducing the intraocular pressure.

Abstract: Drug delivery devices responsive to at least one external stimulus are described, along with methods for their preparation and use. The devices can be configured to respond to the stimulus, providing “on demand” release of one or more deliverables such as pharmaceutical drugs.

Abstract: A method is disclosed for making a porous punctal plug by providing a multi-filament fibrous strand and extrusion coating the fibrous strand with a polymeric material coating and cutting the coated fibrous strand to adequate length for insertion into a mammal's punctal opening.

Abstract: Disclosed are devices and methods for treatment of eye disease. The suprachoroidal space is used as a conduit within which to place a drug delivery device. One such drug delivery device may be a tube, wicking element, bioabsorbable polymer structure, or other configuration of drug delivery substrate. The delivery device may include a port on the proximal end to assist in repeat injection, and may include a reservoir to either collect flow from the aqueous to concentrate it along the length of the device, or act as a repository for injected agent.

Abstract: A bioresorbable drug eluting intravitreal implant system includes a syringe with a chamber containing a medicinal drug. A balloon is releasably secured to a needle where the needle has a central section chamber in fluid communication with a chamber in the syringe. The needle central section has an opening formed through a wall for transporting the medicinal drug to the interior of the balloon subsequent to insertion of the needle through the sclera of a patient's eye.

Abstract: A method and apparatus for administering an active agent such as a medicine to a subject, uses an ocular implant such as a punctal plug, to which the active agent has been applied. The implant is installed at the eye of the subject for administering the active agent via tissues of the eye.

Abstract: The invention relates to a device (1) for use in eye surgery, comprising a container (9) with fluid (5) which is connected via an irrigation line (12) to a surgical handpiece for delivering the fluid (5) for rinsing an eye (3) on which surgery has been performed, wherein a pillar (8), which in particular is electrically adjustable in its height, is provided for supporting the container (9) and for adjusting the height (H) between the container (9) and the surgical handpiece, and wherein a control for adjusting the height of the pillar (8) is provided in order to deliver the fluid (5) from the surgical handpiece into the eye (3) at an irrigation pressure predetermined by the surgeon, wherein pressurizing means (10) are provided which are designed for charging the fluid (5) to be delivered from the container (9) to the irrigation line (12) with an atmospheric overpressure (PATÜ) and wherein the control for adjusting the desired irrigation pressure is designed both for adjusting the height (H) of the pillar (8)

Abstract: A conjunctival cover including an annular generally curved shell having a conjunctival portion structured to conform to and overly at least part of the conjunctiva of an eye. The annular generally partially spherical shell defines a generally central opening. The central opening is sized to leave a cornea of the eye substantially or partially uncovered when the conjunctival cover is applied to the eye.

Abstract: This document discusses, among other things, an apparatus comprising a lacrimal implant insertable at least partially into a lacrimal punctum. The lacrimal implant comprises an implant core, and an implant body. The implant body includes a cavity sized and shaped to receive the implant core. At least one of the implant core and the implant cavity includes a detection device configured to allow automatic detection of the lacrimal implant with a separate detector device.

Abstract: Delivery systems and methods for delivering riboflavin (R/F) and UVA irradiation to the sclera are disclosed. The R/F is delivered and then activated with UVA irradiation through the use of LEDs or optical fibers, thereby causing cross-linking of the collagen tissue. Delivery systems include implantable structures which provide surfaces that conform to the sclera. The delivery systems include various types of structures for delivery of R/F onto the sclera surface. Additionally, the delivery systems include UVA sources which provide irradiation of R/F in sclera collagen tissue.

Abstract: A method for delivering a drug into tissue includes the steps of: providing a drug delivery device having at least one nozzle and a drug contained in a portion of the device; identifying a site for delivery of the drug in or on tissue; placing a portion of the device on or near the site; and delivering the drug into the tissue at the site through at least one nozzle of the device under microjet propulsion.

Abstract: An eye drop assist apparatus and method for sequentially administering an ocular medication into a patient's eyes. A bottle or vial containing liquid eye drops is supported in a holder. First and second nasal locators extend in opposite directions from the holder. The nasal locators are separated by the pupillary distance (typically 60 mm), with the dispensing tip of the bottle located mid-way between. A person administering eye drops abuts the first nasal locator against the top of the patient's nasal bridge while aligning the tip of the bottle directly over a first eye before squeezing the bottle to forcibly expel one or more drops into the first eye. The person then linearly translates the bottle so that the second nasal locator abuts against the top of the patient's nasal bridge while aligning the tip of the bottle directly over a second eye. The bottle is then squeezed again to forcibly expel drops into the second eye.

Abstract: A biomaterial mass is inserted through a punctum into a canaliculus in the lacrimal outflow system with a syringe. The mass has an outer cross section that is less than the inner cross section of the canaliculus. The mass absorbs liquid to swell to form a lacrimal filler or sealing mechanism. The lacrimal filler has an external cross section that conforms to the internal cross section of the canaliculus and a soft outer surface relative to the surrounding tissues to prevent erosion of the canaliculus lining. The lacrimal filler forms an occlusion that prevents the outflow of liquid through the lacrimal outflow system to retain tears within the eye to maintain eye lubrication and wetness. The mass and syringe are provided in kit with a rubber stopper and, optionally, a punctal dilator, an injecting catheter, and an enzyme for dissolving or degrading the lacrimal filler at a later time.

Abstract: The present invention relates to an apparatus and method for delivering a fluid, and particularly, but not exclusively, to an apparatus and method for delivering a fluid to an eye. The apparatus provides a useful device that assists users to accurately deliver fluid to the eye and includes features that make using the apparatus more comfortable.

Abstract: The invention is a device and a method for delivering a dose of a pharmaceutical agent to the eye. The device and method provide a safe and effective way to instill a specified dose of the agent to the eye virtually independent of gravity and posture. The device includes a filter matrix in which the fluid capture and release properties can be modified. The filter matrix is attached to a flexible handle with an impermeable or semipermeable membrane there between.

Abstract: A therapeutic device that can release a therapeutic agent comprising a porous structure coupled to a container comprising a reservoir. The reservoir can comprise a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in a patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the second side. The therapeutic device may comprise a penetrable barrier to inject therapeutic agent into the device when implanted in the patient.

Abstract: An ophthalmic shunt includes a seal or septum through which multiple injections of the therapeutic agent can be made as needed, thereby avoiding repeated injury to the sclera. The therapeutic agent is temporarily carried in a tube connected to the septum. The therapeutic agent release may be rapid or sustained over a period of time.

Abstract: The present disclosure relates to ejector mechanisms and devices for generating a directed stream of droplets, as well as improved methods for delivering an ejected stream of droplets to a target. The device and methods may be useful for the delivery of fluid for ophthalmic, topical, oral, nasal, or pulmonary use, more particularly, for use in the delivery of ophthalmic fluid to the eye. Certain aspects of the disclosure relate to devices and methods for the delivery of a therapeutically effective low dosage volume medicament composition to a target, e.g., by controlling charge, droplet size and/or droplet deposit parameters of the medicament composition.

Abstract: Devices, systems, and methods for treatment of an eye alter aspiration flow from the eye in response to an occlusion of the aspiration conduit pathway. Where aspiration is drawn from the eye using a volumetric pump, the pump can be reversed so as to induce fluid reflux from the aspiration conduit pathway into the eye to help clear the occlusion. The pump may vary the reverse flow in response to sensed aspiration pressure or the like, and the reverse flow may be halted before the pressure within the aspiration conduit pathway adjacent the eye significantly exceeds the irrigation fluid pressure and/or the pressure within the eye. Reflux may alternatively be generated by modulating a vent valve disposed between an irrigation conduit pathway and the aspiration conduit pathway.

Abstract: The present invention relates generally to providing pressurized infusion of liquids and more particularly, is directed to providing a stable and pressurized flow of irrigation fluid to the eye during surgery.

Abstract: The present invention relates generally to providing pressurized infusion of liquids and, more particularly, is directed to providing a stable and pressurized flow of irrigation fluid to the eye during surgery.

Abstract: A first sponge device for use to manipulate and prepare the surface of the epithelium of an eye prior to application of an ophthalmic solution has a handle and a sponge head secured to the handle. The head is made of an absorbent, wicking sponge material and has a non-sharp, tissue preparation surface of predetermined shape for rubbing across the surface of the epithelium layer in order to manipulate the tissue. After the surface is prepared, a second, holding sponge is placed over the eye to act as a reservoir and to hold ophthalmic solution against the eye surface.

Abstract: A delivery device that allows for the sustained release of an agent, particularly useful for the sustained release of a therapeutic agent to limited access regions, such as the posterior chamber of the eye and inner ear. The delivery device is minimally invasive, refillable and may be easily fixed to the treatment area. The delivery device includes a hollow body with an inlet port at its proximal end for insertion of the agent, a reservoir for holding the agent and a delivery mechanism for the sustained delivery of the agent from the reservoir to the patient.

Abstract: The method and system disclosed herein uses a pulsatile, dilatory bubble at the tip of a catheter to facilitate tissue separation and ease catheter insertion for, among other applications, delivery of therapeutics to the posterior of the eye while reducing procedure-related trauma. In some implementations, the method is extended to other dilatory and catheter-insertion applications elsewhere in the body. In brief, the disclosure discusses iteratively injecting liquid through a catheter to form a bubble near the distal tip of the catheter. The liquid is withdrawn to create a void, and the catheter is advanced into the void. The process is repeated until the distal tip of the catheter reaches the target location.

Abstract: A peptide-POD with ability to penetrate and deliver fluorophores, siRNA, DNA and quantum dots to cells in culture and retinal and ocular tissues in vivo is provided herein. POD couples to adenovirus vectors, enhancing tropism for certain cells, potentially providing a safer and more efficacious method to deliver molecules to ocular and other tissues in vivo. POD constructs are therapeutic delivery vehicles for treating cells and tissues, including ocular cells and tissues suffering from retinal degeneration.